Blog Post

“Anthropic wants to develop its own drugs” is more than a striking headline. It signals a major shift in how artificial intelligence companies may participate in healthcare innovation. Instead of only selling tools to pharmaceutical companies, Anthropic is now moving toward direct involvement in drug discovery through its new scientific platform, Claude Science. According to [Reuters] the company has launched an AI research workbench designed to help scientists streamline research, analyze data, manage complex computing workflows, and support life sciences development. Reuters also reported that Anthropic is launching its own preclinical drug programs focused on neglected diseases.

This matters because AI drug discovery is moving from theory to infrastructure. Anthropic’s own [Anthropic] describes a research environment that brings together databases, coding tools, scientific workflows, computing resources, figures, manuscripts, and auditable outputs. The platform includes more than 60 curated skills and connectors across genomics, single-cell biology, proteomics, structural biology, and cheminformatics.

Why Anthropic’s Move Is Important

Most AI companies entering healthcare have focused on productivity tools: helping researchers review literature, write code, summarize papers, analyze datasets, or prepare regulatory documents. Anthropic is doing that too, but the company’s stated plan to develop drugs internally changes the conversation. As [The Verge] explains, Anthropic is not only positioning Claude as a tool for drugmakers; it is also placing itself closer to becoming a participant in the drug discovery process.

That creates both opportunity and tension. On one hand, building drugs internally could give Anthropic better feedback loops. Scientists using Claude Science on real discovery problems may identify weaknesses in the model, gaps in data access, and workflow bottlenecks that ordinary software testing would miss. On the other hand, if Anthropic sells AI tools to pharmaceutical companies while also pursuing its own drug candidates, it may need clear governance rules around data use, conflicts of interest, intellectual property, and transparency.

Why Neglected Diseases Matter

Anthropic’s reported focus on neglected diseases is especially important for the Global South, including Sub-Saharan Africa. The [WHO] explains that these diseases are most common in impoverished tropical communities and can cause serious health, social, and economic consequences.

This is where AI drug discovery could become genuinely transformative. Traditional pharmaceutical research often follows market incentives. Diseases that affect wealthier populations tend to attract more investment, while conditions concentrated in low-income settings are often underfunded. If AI reduces early-stage discovery costs, improves target identification, and helps generate better molecule candidates faster, it could make neglected disease research more feasible.

AI Will Not Replace Real-World Experiments

The excitement around Anthropic’s drug discovery plans should be balanced with realism. AI can help scientists generate hypotheses, search chemical space, analyze biological data, and prioritize candidates. But it cannot yet replace real-world experiments. The Verge reported that experts cautioned AI-designed drugs still face a long path to market, including testing for safety, toxicity, efficacy, stability, manufacturing feasibility, and clinical benefit in humans.

This is why Claude Science’s emphasis on auditable outputs matters. Anthropic says the platform can show code, message history, plain-language explanations, and reproducible artifacts. In drug discovery, this is not a small feature. Reproducibility is central to scientific trust. If a model suggests a molecule, researchers must be able to understand how the suggestion was generated, what data supported it, what assumptions were made, and where uncertainty remains.

What Commercial Entities Should Do Differently

Commercial AI and biotech companies should treat access as a design requirement, not an afterthought. If Anthropic or any AI company identifies a promising candidate for a neglected disease, the next questions should be practical: Who will run trials? Where will trials be conducted? Will affected populations be included? How will pricing work? Can manufacturing be scaled affordably? Will local health systems be able to deliver the treatment?

Implications for the Global South

For the Global South, Anthropic’s move should be viewed as both a signal and an invitation. The signal is that frontier AI companies now see healthcare and life sciences as major areas of impact. The invitation is for governments, universities, NGOs, hospitals, and innovation hubs to shape the agenda early.

If AI drug discovery focuses only on wealthy markets, it may widen health inequities. But if the field prioritizes neglected diseases, diverse datasets, African trial sites, ethical governance, and affordability, it could help close long-standing treatment gaps. This requires stronger partnerships between AI labs, public health agencies, local scientists, regulators, community organizations, and funders.

Conclusion: The Real Test Is Access

Anthropic wants to develop its own drugs, and that is a major milestone for AI in healthcare. But the success of this move will not be measured only by whether Claude Science can suggest promising molecules. The real test will be whether AI-supported discovery can produce safe, effective, affordable treatments for diseases that have been ignored for too long.

For neglected diseases and underserved populations, the opportunity is significant. AI could reduce early research costs, widen the pipeline of viable therapies, and help scientists explore biological questions faster. But without strong regulation, ethical data governance, clinical evidence, local research participation, and access-first business models, faster discovery may still fail to become better healthcare.

The future of AI drug discovery should not be only about who builds the smartest model. It should be about who benefits first, who participates in the evidence, and whether innovation reaches the communities that need it most.